{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:19Z","timestamp":1786988119566,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejpb.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:37:23Z","timestamp":1648064243000},"page":"56-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model"],"prefix":"10.1016","volume":"174","author":[{"given":"Felix","family":"Funk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naja","family":"Nyffenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Alexander","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.03.006_b0005","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S2352-3026(19)30264-9","article-title":"Intravenous iron: a framework for changing the management of iron deficiency","volume":"7","author":"Auerbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejpb.2022.03.006_b0010","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s12325-020-01323-z","article-title":"Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency","volume":"37","author":"Macdougall","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejpb.2022.03.006_b0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/17435390.2019.1572809","article-title":"Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease","volume":"13","author":"Alphand\u00e9ry","year":"2019","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.ejpb.2022.03.006_b0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40262-014-0218-2","article-title":"Evaluating plasma pharmacokinetics of intravenous iron formulations: judging books by their covers?","volume":"54","author":"Pai","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2022.03.006_b0025","article-title":"Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice","volume":"26","author":"Nikravesh","year":"2020","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.ejpb.2022.03.006_b0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"issue":"23","key":"10.1016\/j.ejpb.2022.03.006_b0035","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1039\/C5CS00541H","article-title":"In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles","volume":"44","author":"Arami","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejpb.2022.03.006_b0040","unstructured":"European Medicines Agency, Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product, 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed_en.pdf. [access date 15 Jan 2022]."},{"issue":"2","key":"10.1016\/j.ejpb.2022.03.006_b0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.1999.01179.x","article-title":"Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography","volume":"104","author":"Beshara","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ejpb.2022.03.006_b0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/nano8010010","article-title":"Comparative evaluation of U.S. brand and generic intravenous sodium ferric gluconate complex in sucrose injection: biodistribution after intravenous dosing in rats","volume":"8","author":"Beekman","year":"2017","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ejpb.2022.03.006_b0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.vascn.2013.04.005","article-title":"Biodistribution and predictive hepatic gene expression of intravenous iron sucrose","volume":"68","author":"Elford","year":"2013","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejpb.2022.03.006_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/nano8020101","volume":"8","author":"Matta","year":"2018","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ejpb.2022.03.006_b0065","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/acs.molpharmaceut.8b01215","article-title":"Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach","volume":"16","author":"Neu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.03.006_b0070","series-title":"Harrison\u2019s Principles of Internal Medicine","article-title":"Anemia and Polycythemia","author":"Adamson","year":"2018"},{"key":"10.1016\/j.ejpb.2022.03.006_b0075","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3390\/ijms23042140","article-title":"Criticality of surface characteristics of intravenous iron-carbohydrate nanoparticle complexes: implications for pharmacokinetics and pharmacodynamics","volume":"23","author":"Funk","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2022.03.006_b0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2125.2009.03585.x","article-title":"Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): considerations to optimize study design","volume":"69","author":"Dissanayake","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2022.03.006_b0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.23682","article-title":"Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin","volume":"89","author":"Evstatiev","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejpb.2022.03.006_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.vascn.2017.12.001","article-title":"Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations","volume":"91","author":"Span","year":"2018","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"5","key":"10.1016\/j.ejpb.2022.03.006_b0095","doi-asserted-by":"crossref","first-page":"e0196684","DOI":"10.1371\/journal.pone.0196684","article-title":"The hypoxia inducible factor\/erythropoietin (EPO)\/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia","volume":"13","author":"Landau","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2022.03.006_b0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.clinthera.2019.12.010","article-title":"Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia","volume":"42","author":"Ding","year":"2020","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.ejpb.2022.03.006_b0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1053\/j.ajkd.2010.05.009","article-title":"Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis","volume":"56","author":"Van Wyck","year":"2010","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.ejpb.2022.03.006_b0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/clinchem\/26.5.635","article-title":"Interference of imferon in colorimetric assays for iron","volume":"26","author":"Huisman","year":"1980","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejpb.2022.03.006_b0115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/clinchem\/22.4.524","article-title":"Serum iron determination in patients receiving therapy with iron dextran","volume":"22","author":"McIntosh","year":"1976","journal-title":"Clin. Chem."},{"issue":"16","key":"10.1016\/j.ejpb.2022.03.006_b0120","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.4155\/bio.11.180","article-title":"Analysis of total and transferrin-bound iron in human serum for pharmacokinetic studies of iron-sucrose formulations","volume":"3","author":"Goggin","year":"2011","journal-title":"Bioanalysis"},{"issue":"11","key":"10.1016\/j.ejpb.2022.03.006_b0125","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3324\/haematol.2020.250803","article-title":"Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways","volume":"106","author":"Garbowski","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejpb.2022.03.006_b0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1208\/s12248-018-0265-y","article-title":"Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?","volume":"20","author":"Marden","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2022.03.006_b0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1592\/phco.27.3.343","article-title":"Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejpb.2022.03.006_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yrtph.2018.05.014","article-title":"In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations","volume":"97","author":"Pai","year":"2018","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.ejpb.2022.03.006_b0145","first-page":"345","article-title":"The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose","volume":"60","author":"Funk","year":"2010","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.ejpb.2022.03.006_b0150","doi-asserted-by":"crossref","first-page":"F1563","DOI":"10.1152\/ajprenal.00307.2019","article-title":"Parenterial iron sucrose-induced renal preconditioning: differential ferritin heavy and light chain expression in plasma, urine, and internal organs","volume":"317","author":"Johnson","year":"2019","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.ejpb.2022.03.006_b0155","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/clinchem\/45.6.898","article-title":"Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran","volume":"45","author":"Seligman","year":"1999","journal-title":"Clin. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.ejpb.2022.03.006_b0160","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2362.2002.0320s1042.x","article-title":"Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients","volume":"32","author":"Esposito","year":"2002","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2022.03.006_b0165","unstructured":"US_FDA, Office of Generic Drugs 2021 Annual Report, (2022). https:\/\/www.fda.gov\/media\/156066\/download. [access date 15 February 2022]."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:46:53Z","timestamp":1760546813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":33,"alternative-id":["S0939641122000546"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.03.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}